Philips Unveils Integrated Interventional Hemodynamic System with...

Philips Unveils Integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3

Healthcare Tech Outlook | Monday, May 24, 2021

The IntelliVue X3 patient monitor can be attached to the patient from any location in the hospital. It will remain with them during the interventional process, providing continuous monitoring and registration of their vital signs in the IntelliVue IT solution.

FREMONT, CA: Royal Philips, a global leader in health technology, announced the integration of its Interventional Hemodynamic System and market-leading portable Patient Monitor IntelliVue X3, offering advanced hemodynamic (blood flow) measurements at the tableside in the cath lab and continuous monitoring of key vital signs across the patient journey. The integration enables monitoring during image-driven procedures on the Philips Image Guided Therapy System” Azurion,” enhancing workflow and allowing for prompt clinical decision-making during interventional cardiology procedures and beyond. The solution was unveiled at the American College of Cardiology’s 70th Annual Scientific Session and Expo held digitally on May 15-17.

“Philips Interventional Hemodynamic System with Patient Monitor IntelliVue X3 is a unique combination made possible by our strengths in patient monitoring and image-guided therapy,” said Ronald Tabaksblat, General Manager Image-Guided Therapy Systems, Philips. “Bringing advanced hemodynamic measurements to the tableside as an integrated part of our Azurion image-guided therapy system, it helps allow clinicians to assess the condition of the patient in real time during an intervention, without leaving the sterile field. It also streamlines workflows, providing continuous monitoring of the patient during every step of their care path, enhancing patient safety and confidence.”

Health systems aim to provide consistently high-quality patient care while also leveraging the interventional room to treat more patients and treat the critically ill more quickly. As patients are transferred from holding areas to the interventional room and then to recovery areas, uninterrupted patient monitoring will aid clinical decision-making and the prompt identification of possible adverse effects at any point of the patient journey.

The monitor, which includes a 12-lead diagnostic ECG, eliminates the need to re-cable the patient or reconnect monitoring, resulting in decreased procedural planning time, increased staff performance, and, eventually, a better patient experience. The IntelliVue X3 patient monitor can be attached to the patient from any location in the hospital. It will remain with them during the interventional process, providing continuous monitoring and registration of their vital signs in the IntelliVue IT solution.

Clinical staff can track all of the patient’s vital signs, including pulse oximetry and end-tidal CO2, conduct hemodynamic analyses and 12-lead ECG acquisitions, and relay data and waveforms from the lab’s control room to the Azurion tableside display after attaching the IntelliVue X3 to its docking station at the tableside of the Azurion device. The Azurion tableside Touch Screen Module allows interventionalists to assess data from the tableside, enabling them to stay focused on their patients. The system includes iFR (instant wave-free Ratio) measurements, a hyperemia-free technique special to Philips that offers useful functional knowledge about the magnitude of coronary artery lesions.

Philips’ Interventional Hemodynamic System with Patient Monitor IntelliVue X3 integrates with Azurion, the company’s next-generation image-guided therapy system, allowing clinicians to quickly and comfortably conduct procedures with a unique user interface, allowing lab output to be optimized and superior treatment to be provided. Philips will demonstrate its strategies for the diagnosis and treatment of Structural Heart Disease at ACC.21 to remove the obstacles associated with complicated procedures by assisting in delivering clinical trust where it is most needed: at the point of treatment

Weekly Brief